Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor

Posterior pituitary tumors (PPT) expressing thyroid transcription factor-1 (TTF-1) are extremely rare low-grade neoplasms. The recent discovery of BRAF mutations in these tumors offers a potential alternative treatment using targeted therapies. We present the case of a 57-year-old female with recurr...

Full description

Saved in:
Bibliographic Details
Published in:Acta neurochirurgica 2022-03, Vol.164 (3), p.737-742
Main Authors: Grenier-Chartrand, Flavie, Barrit, Sami, Racu, Marie Lucie, Luce, Sylvie, Spitaels, Julien, Sadeghi-Meibodi, Niloufar, Lebrun, Laetitia, Salmon, Isabelle, Lefranc, Florence, De Witte, Olivier
Format: Article
Language:English
Subjects:
Brain cancer
Brain tumors
Case Report- Pituitaries
Female
Humans
Imidazoles - therapeutic use
Interventional Radiology
Medicine
Medicine & Public Health
Middle Aged
Minimally Invasive Surgery
Mutation
Mutation - genetics
Neurology
Neuroradiology
Neurosurgery
Oximes - therapeutic use
Pituitary (posterior)
Pituitary gland
Pituitary Neoplasms - drug therapy
Pituitary Neoplasms - genetics
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf - genetics
Surgical Orthopedics
Thyroid
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Posterior pituitary tumors (PPT) expressing thyroid transcription factor-1 (TTF-1) are extremely rare low-grade neoplasms. The recent discovery of BRAF mutations in these tumors offers a potential alternative treatment using targeted therapies. We present the case of a 57-year-old female with recurrent BRAF V600E-mutated TTF-1-positive PPT treated with a BRAF inhibitor monotherapy (dabrafenib) leading to tumor regression. After 18 months of uninterrupted treatment, ongoing radiological tumor regression was observed and the patient remained asymptomatic without any significant adverse event. BRAF inhibitor is potentially a valuable treatment option for recurrent TTF-1-positive PPT with BRAF mutation.
ISSN:0001-6268
0942-0940
DOI:10.1007/s00701-022-05109-w